O&G SAQs · Antenatal care — genetic screening
Genetic carrier screening — structured SAQ (15 marks)
FRANZCOG-format structured SAQ on reproductive carrier screening: the three-gene panel, autosomal recessive risk, pre-test counselling and timing, and the reproductive options after a both-partner positive result. Per-sub-part marking rubric included.
On this page
Study tools
Target exams
How this SAQ is marked
Twelve SAQs, 180 marks, two 2-hour papers — roughly 15 marks and 20 minutes each. Marks come from specifics: the three named genes, the one-in-four risk, the preconception timing rationale, and the full list of reproductive options. Write in short labelled points. [1]
Reveal model answer and mark schemeShowHide
(a) Definition and the three-gene panel (3 marks)
One mark for the definition, one for naming all three genes, one for the universal-offer rationale.
- Definition: reproductive carrier screening is the testing of healthy individuals to identify carriers of autosomal recessive or X-linked conditions before or early in pregnancy, so couples can make informed reproductive choices.[1]
- The three genes: cystic fibrosis, spinal muscular atrophy and fragile X syndrome.[1]
- Offer to everyone planning or in early pregnancy, regardless of family history, because most affected children are born to couples with no family history.[1]
(b) Inheritance and per-pregnancy risk (3 marks)
One mark for AR mechanism, one for the one-in-four figure, one for carrier-vs-affected distinction. [1]
- Autosomal recessive: both parents must be carriers for the child to be at risk; carriers are themselves unaffected.[1]
- Per pregnancy: one in four chance of an affected child, one in two chance of a carrier, one in four chance of neither.[1]
- Contrast with X-linked (fragile X): the woman carries; sons at risk of the full mutation; premutation can expand across generations.[1][9]
(c) Pre-test counselling and timing (4 marks)
One mark for timing, one for the timing rationale, one for residual risk, one for non-directive framing. [1]
- Timing: ideally before conception, so all options remain open; if already pregnant, first trimester.[1]
- Rationale: preconception a result allows IVF with PGT, donor gametes, or choosing not to conceive; in pregnancy options narrow to prenatal diagnosis and possible termination.[1][5]
- Residual risk: a negative screen reduces but does not eliminate risk — never say 'zero risk'.[1][6]
- Non-directive: explain what positive, negative and variant-of-uncertain-significance results would mean; support any reproductive choice.[1]
(d) Reproductive options after a both-partner positive result (5 marks)
One mark per option, max five.
- Accept the risk — conceive naturally with or without postnatal testing.[1]
- Natural conception with prenatal diagnosis (CVS or amniocentesis) and the option of termination of an affected pregnancy.[1]
- IVF with pre-implantation genetic testing (PGT) — select unaffected embryos.[5]
- Donor gametes (sperm, eggs or embryos) from a non-carrier.[1]
- Adoption, or choosing not to have children.[1]
- State referral to clinical genetics for counselling on SMA severity, prognosis and support.[1]
- Evidence it changes decisions: in Mackenzie's Mission, 76.6% of newly at-risk couples had used or planned a reproductive intervention within 3 months, with low decisional regret.[2]
- Fragile X positive: counsel FXPOI risk and family cascade in addition to reproductive risk.[9]
References5ShowHide
- [1]Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) Genetic Carrier Screening (C-Obs 63), Interim Update July 2024 RANZCOG Statement, 2024.Source
- [9]Morbey EJ, Day FR, Wright DJ, et al. Large-scale analysis of FMR1 CGG repeat length and risk of premature ovarian insufficiency in over 92 000 women Hum Reprod, 2026.PMID 42001465
- [6]Grody WW, Thompson BH, Gregg AR, et al. ACMG position statement on prenatal/preconception expanded carrier screening Genet Med, 2013.PMID 23619275
- [2]Kirk EP, Delatycki MB, Archibald AD, et al. Nationwide, Couple-Based Genetic Carrier Screening N Engl J Med, 2024.PMID 39565987
- [5]Capalbo A, Fabiani M, Caroselli S, et al. Clinical validity and utility of preconception expanded carrier screening for the management of reproductive genetic risk in IVF and general population Hum Reprod, 2021.PMID 34021342